Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 27, 2018 | June 29, 2018 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | June 12, 2018 | June 14, 2018 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | October 02, 2026 | October 06, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director · Chief Executive Officer | February 17, 2026 | February 19, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, COO | June 29, 2018 | July 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date June 27, 2018 · Filed June 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.15 · Expires 2028-06-27 | Direct | 15,000 |
Reported balance
After 2018-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-27 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
INFINITY PHARMACEUTICALS, INC.
Report date June 12, 2018 · Filed June 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,845 |
Reported balance
After 2018-06-12 transaction · row 1
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 22,857 · Balance 45,845 F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12 | Direct | 20,000 |
Reported balance
After 2018-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-12 · Grant · Acquired 20,000 · Balance 20,000 F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12 | Direct | 4,000 |
Reported balance
After 2018-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-12 · Grant · Acquired 4,000 · Balance 4,000 F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.
F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 27,393 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
Solid Biosciences Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 141,585 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Exercise / conversion · Acquired 3,440 · Balance 141,585 F1: Restricted stock units convert to common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,440 |
Reported balance
After 2026-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-02 · Exercise / conversion · Disposed 3,440 · Balance 3,440 F1: Restricted stock units convert to common stock on a one-for-one basis. F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert to common stock on a one-for-one basis.
F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.
Stoke Therapeutics, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.09 · Expires 2036-02-16 | Direct | 193,000 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 193,000 · Balance 193,000 F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2030-02-15 | Direct | 129,000 |
Reported balance
After 2026-02-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-17 · Grant · Acquired 129,000 · Balance 129,000 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.
F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,699 |
Ending reported balance
After 2018-06-29 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-06-29 · Exercise / conversion · Acquired 23,375 · Balance 70,074 Row 2 · 2018-06-29 · Sale · Disposed 4,741 · Balance 65,333 F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89). F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2018-06-29 · Sale · Disposed 18,634 · Balance 46,699 F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.89 · Expires 2025-07-20 | Direct | 10,625 |
Reported balance
After 2018-06-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-29 · Exercise / conversion · Disposed 23,375 · Balance 10,625 F5: The option vests in 16 quarterly installments from 7/21/2015. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,306 |
Reported balance
Holding disclosure · report date 2018-06-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,306 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).
F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).
F5: The option vests in 16 quarterly installments from 7/21/2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2016 Filed Feb 4, 2016 23:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,652 | $92.73 | $153,189.96 |
DisclosureSEC source: 0001209191-16-095845 · doc4.xml · nonDerivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F2 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F4 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $92.73 (range $92.34 to $93.20). Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $91.68 | $110,016.00 |
DisclosureSEC source: 0001209191-16-095845 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,651 F2 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F4 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $91.68 (range $91.33 to $92.23). Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,232 | $90.97 | $384,985.04 |
DisclosureSEC source: 0001209191-16-095845 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,851 F2 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F4 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $90.97 (range $90.32 to $91.30). Read SEC document |
| February 03, 2016 Filed Feb 4, 2016 23:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $89.90 | $449,500.00 |
DisclosureSEC source: 0001209191-16-095845 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,083 F2 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $89.90 (range $89.31 to $90.27). F4 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2016 Filed Feb 4, 2016 23:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 34,482 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-16-095845 · doc4.xml · derivative · entry 7 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,482 Underlying: Common Stock · 34,482 shares Expires 2016-02-01 F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| February 02, 2016 Filed Feb 4, 2016 23:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 17,299 | $0.01 | $172.99 |
DisclosureSEC source: 0001209191-16-095845 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,083 F1 · shares: Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,685 | $126.62 | $339,974.70 |
DisclosureSEC source: 0001209191-15-078179 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,784 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $126.62 (range $126.34 to $126.93). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,865 | $125.98 | $612,892.70 |
DisclosureSEC source: 0001209191-15-078179 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,469 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $125.98 (range $125.33 to $126.28). Read SEC document |
| October 30, 2015 Filed Nov 3, 2015 23:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,800 | $124.95 | $349,860.00 |
DisclosureSEC source: 0001209191-15-078179 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,334 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $124.95 (range $124.33 to $125.30). Read SEC document |
| July 21, 2015 Filed Jul 23, 2015 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-15-062194 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2025-07-20 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/21/2015. Read SEC document |
| May 15, 2015 Filed May 18, 2015 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $126.99 | $12,699.00 |
DisclosureSEC source: 0001209191-15-043953 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,134 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2015 Filed May 18, 2015 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 178 | $125.84 | $22,399.52 |
DisclosureSEC source: 0001209191-15-043953 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,234 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2015 Filed May 18, 2015 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $123.85 | $12,385.00 |
DisclosureSEC source: 0001209191-15-043953 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,412 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $127.83 | $63,915.00 |
DisclosureSEC source: 0001209191-15-028985 · doc4.xml · nonDerivative · entry 6 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,134 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $127.83 (range $127.39 to $128.19). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $126.65 | $126,650.00 |
DisclosureSEC source: 0001209191-15-028985 · doc4.xml · nonDerivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,634 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $126.65 (range $126.29 to $127.07). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,815 | $125.69 | $353,817.35 |
DisclosureSEC source: 0001209191-15-028985 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,634 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $125.69 (range $125.28 to $126.24). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,327 | $124.87 | $165,702.49 |
DisclosureSEC source: 0001209191-15-028985 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,449 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $124.87 (range $124.28 to $125.24). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $123.52 | $24,704.00 |
DisclosureSEC source: 0001209191-15-028985 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,776 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $123.52 (range $123.10 to $123.93). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $122.44 | $24,488.00 |
DisclosureSEC source: 0001209191-15-028985 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,976 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $122.44 (range $122.10 to $122.78). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,100 | $113.13 | $576,963.00 |
DisclosureSEC source: 0001209191-15-016654 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,176 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $113.13 (range $112.99 to $113.39). Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,250 | $112.66 | $591,465.00 |
DisclosureSEC source: 0001209191-15-016654 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,276 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $112.66 (range $111.99 to $112.98). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009887 · doc4.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,700 | $0.01 | $207.00 |
DisclosureSEC source: 0001209191-15-009887 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,526 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| December 12, 2014 Filed Dec 16, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,880 | $120.44 | $346,867.20 |
DisclosureSEC source: 0001209191-14-075844 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,826 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $120.44 (range $120.22 to $120.84). Read SEC document |
| December 12, 2014 Filed Dec 16, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,162 | $119.82 | $378,870.84 |
DisclosureSEC source: 0001209191-14-075844 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,706 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $119.82 (range $119.21 to $120.20). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2014 Filed Nov 3, 2014 22:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 75,000 | $0.01 | $750.00 |
DisclosureSEC source: 0001209191-14-065918 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,868 F1 · shares: Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on October 30, 2017 (or, if later, the day following the earnings release for the third quarter of 2017) if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 1, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 16,992 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · derivative · entry 21 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,383 Underlying: Common Stock · 16,992 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 18,126 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · derivative · entry 20 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,124 Underlying: Common Stock · 18,126 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/25/2012. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 16,993 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · derivative · entry 19 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,789 Underlying: Common Stock · 16,993 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 11,330 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · derivative · entry 18 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,062 Underlying: Common Stock · 11,330 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/13/2011. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 16,993 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · derivative · entry 17 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,195 Underlying: Common Stock · 16,993 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2011. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 11,329 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · derivative · entry 16 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,329 shares Expires 2020-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/14/2010. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 13,594 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · derivative · entry 15 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,594 shares Expires 2020-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/04/2010. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,267 | $0.00 Strike: $33.28 | $0.00 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · derivative · entry 14 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,267 shares Expires 2019-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/16/2009. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 22,156 | $113.90 | $2,523,568.40 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 12 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,868 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $113.90 (range $113.61 to $114.34). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 28,751 | $113.10 | $3,251,738.10 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 11 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,024 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $113.10 (range $112.61 to $113.59). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 43,112 | $112.21 | $4,837,597.52 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 10 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,775 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $112.21 (range $111.61 to $112.60). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14,007 | $111.31 | $1,559,119.17 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 9 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,887 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $111.31 (range $110.61 to $111.60). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 16,992 | $45.11 | $766,509.12 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 8 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 18,126 | $48.74 | $883,461.24 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 7 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 16,993 | $37.86 | $643,354.98 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 6 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,330 | $51.75 | $586,327.50 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 5 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 16,993 | $38.80 | $659,328.40 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 4 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,329 | $33.82 | $383,146.78 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 13,594 | $39.05 | $530,845.70 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,267 | $33.28 | $75,445.76 |
DisclosureSEC source: 0001209191-14-060584 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2014 Filed Jul 17, 2014 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-14-047934 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2024-07-14 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/15/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008360 · doc4.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,700 | $0.01 | $207.00 |
DisclosureSEC source: 0001209191-14-008360 · doc4.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,868 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 34,000 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-13-038699 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2023-07-29 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.